is the most common type of cancer found in infants. Neuroblastoma is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. This cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is classified as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. Neuroblastoma is a cancer which starts in primitive nerve cells. It rarely occurs after age around 10 years. According to America Cancer Society, neuroblastoma accounts for over 7% of the total cancer cases in age group of 0 to 14 years of age. Some of the most common symptoms of the neuroblastoma are firm mass in the abdomen, enlarged stomach, weight, anemia, crankiness, fever, bone pain, bulging eyes, dark circles around the eyes, weakness, and high blood pressure
North America held substantial revenue share of the overall oxygen therapy market The increasing number of product approvals and high R&D investments are the key growth drivers responsible for the largest share of the market in this region. It is followed by Europe in terms of revenue share owing to the presence of favorable government initiatives for improving respiratory care, such as European Committee for Hyperbaric Medicine (ECHM), involved in promoting awareness pertaining to the treatment.This report on global Neuroblastoma Treatmentis segmented on the basis of Neuroblastoma Treatment application, end-use industries using Neuroblastoma Treatment for wide range of end-use applications and market size in various geographical regions.
This report identifies the
Neuroblastoma Treatment market
size in for the year 2016-2021, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to Neuroblastoma Treatment market.
This report segments global neuroblastoma market on the basis of type, procedures, and regional market as follows:
- On the basis of treatment categories of Neuroblastoma Treatment, this report is segmented into five major treatment. Some of the major treatment covered in this report are as follows: Surgery, Chemotherapy, High-dose chemotherapy with stem cell support, Monoclonal antibody treatment, Radiotherapy and Others
- On the basis of drug categories of Neuroblastoma Treatment, this report is segmented into five major drugs. Some of the major drugs covered in this report are as follows: Xalkori (crizotinib), Adriamycin PFS (Doxorubicin Hydrochloride), Clafen (Cyclophosphamide), Vincasar PFS (Vincristine Sulfate) and Others
- This report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for Neuroblastoma Treatment in each of the region.
This report identifies all the major companies operating in the global Neuroblastoma Treatment market. Some of the major companies’ profiles in detail are as follows:
- Seattle Children’s
- Cure Search
- Texas Children’s
- NANTGE Healthcare